WOS
Permanent URI for this collectionhttps://hdl.handle.net/11443/932
Browse
4 results
Search Results
Item Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study(TAYLOR \& FRANCIS LTD, 2022-01-01) Basoglu, Tugba; Sakin, Abdullah; Erol, Cihan; Ozden, Ercan; cabuk, Devrim; Cilbir, Ebru; Tataroglu ozyukseler, Deniz; Ayhan, Murat; Sendur, Mehmet Ali; Dogan, Mutlu; Oksuzoglu, Berna; Eryilmaz, Melek Karakurt; Er, Ozlem; Tasci, Elif Senocak; Ozyurt, Neslihan; Dulgar, Ozgecan; Ozen, Mirac; Hacibekiroglu, Ilhan; Oner, Irem; Bekmez, Esma Turkmen; Cagri Yildirim, Hasan; Yalcin, Suayib; Paydas, Semra; Yekeduz, Emre; Aksoy, Asude; Ozcelik, Melike; Oyman, Abdilkerim; Almuradova, Elvina; Karabulut, Bulent; Demir, Nazan; Dincer, Murat; Ozdemir, Nuriye; Erdem, Dilek; Ak, Naziye; Inal, Ali; Salim, Derya Kivrak; Deniz, Gulhan Ipek; Sakalar, Teoman; Gulmez, Ahmet; Kacan, Turgut; Ozdemir, Ozlem; Alan, Ozkan; Unal, Caglar; Karakas, Yusuf; Turhal, Serdar; Yumuk, Perran FuldenNeoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18-86). Most frequent NACT regimens used were FLOT (65.4\%), DCF (17.4\%) and ECF (8.1\%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2\%, R0 resection rate 86.4\%, and D2 dissection rate was 66.8\%. Rate of pCR and near-CR (24\%), and R0 resection (84\%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1-154 months). Estimated median overall survival (OS) was 58.4months (95\% CI: 35.2-85.7) and disease-free survival (DFS) was 50.7 months (95\% CI: 25.4-75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68\%). We still do not know which NACT regimen is the best choice for daily practice. Clinicians should tailor treatment regimens according to patients' multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.Item Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial(GALENOS PUBL HOUSE, 2020-01-01) Demir, Atakan; Mandel, Nil Molinas; Paydas, Semra; Demir, Gokhan; Er, Ozlem; Turhal, Nazim Serdal; Bavbek, Sevil; Eralp, Yesim; Saip, Pinar Mualla; Guler, Emine Nilufer; Aydiner, Adnan; Uluc, Basak Oyan; Kilickap, Sadettin; Uskent, Necdet; Karadurmus, Nuri; Kaplan, Mehmet Ali; Yanmaz, Mustafa Teoman; Demir, Hacer; Alan, Ozkan; Korkmaz, Taner; Olgun, Polat; Uysal, Ozlem Sonmez; Altundag, Kadri; Gunduz, Seyda; Gunaldi, Meral; Sari, Murat; Beypinar, Ismail; Basaran, GulBackground: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14\%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.Item Predictive Values of Systemic Inflammation Index in Prognosis of Patients with Laryngeal Cancer(KARE PUBL, 2020-01-01) Demir, Atakan; Alan, Ozkan; Surmeli, MehmetObjectives: Laryngeal cancer is the most common cancer in head and neck cancer group, of which it constitutes 75\%. Squamous cell carcinoma (SCC) is the most common histological subtype. Systemic or local inflammation is a well known promotor for cancer development and progression. Systemic immune inflammation index (S II) has been reported as an independent prognostic parameter in various cancers. We aimed to evaluate the capability of SII in predicting the risk of recurrence in patients with operable laryngeal cancer. Methods: We retrospectively collected the data of 100 laryngeal SCC patients who underwent surgery between 2016 and 2018. Neutrophil, lymphocyte, and platelet (Plt) counts were recorded. The SII was calculated as follows: SII= Neutrophile counts {*}platelet counts/lymphocyte counts. Results: SI index was found to be an independent prognostic factor as affecting disease recurrence (p<0.05). We found that patients with SII >891 had a risk of disease recurrence of approximately three times more than patients with SII = <891.78 (HR: 3.06 (95\% CI: 3.42-132.64). Conclusion: This was the first study to demonstrate that preoperative SI index is a simple and powerful independent predictive index that predicts the risk of disease recurrence in patients with laryngeal cancer.Item Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment(BMC, 2019-01-01) Demir, Atakan; Alan, Ozkan; Oruc, ErtugrulBackgroundRectum cancer is a type of colorectal cancer. Its etiology and etiopathogenesis are similar to other colon diseases. We aimed to evaluate the tumor budding for predicting prognosis of resected rectum cancer patients.MethodsWe retrospectively collected the data of 75 operated rectum adenocarcinoma patients who were treated neoadjuvant chemoradiotherapy between 2013 and 2018 in Umraniye Research and Training Hospital and Acbadem University Medical Oncology Outpatient Clinic. Tumor budding was investigated as a prognostic factor for disease-free survival.ResultsThis study included 75 rectum cancer patients and 51 were male (68\%). Median age was 56 (range 19 to 77years). There were 29 (39\%) and 46 (61\%) patients in tumor budding low-intermediate and high groups respectively. In multivariate analysis, tumor budding was found to be an independent prognostic factor for disease-free survival (p=0.00).ConclusionsAccording to our study, having high tumor budding suggests a high likelihood of relapse. Therefore, we might need additional follow-up protocol in these patients.